Van Damme P
Neurology Department, KULeuven University Hospital, Laboratory of Neurobiology, KULeuven and Vesalius Research Center, VIB Leuven, Herestraat 49 - B 3000 Leuven.
Verh K Acad Geneeskd Belg. 2009;71(4):241-50.
The progressive degeneration of motor neurons in amyotrophic lateral sclerosis (ALS) is a complex and multifactorial process. Both excitotoxicity (excessive stimulation of glutamate receptors) and a shortage of the vascular endothelial growth factor (VEGF) have been implicated in the disease pathogenesis. In this study, both disease mechanisms were further characterized and their therapeutic potential was evaluated. Motor neurons were found to be particularly vulnerable to AMPA receptor stimulation (one subtype of glutamate receptors) and the toxicity was initiated by the influx of calcium ions through the AMPA receptors. Only AMPA receptors that lack a certain subunit (GluR2) are permeable to calcium ions, and compared to other neurons motor neurons had low GluR2 levels. Reducing GluR2 levels aggravated motor neuron death in culture and accelerated the process of motor neuron degeneration in vivo. The regulation of GluR2 expression was investigated further. Astrocytes were found to influence neuronal GluR2 expression and thus their vulnerability to excitotoxicity. In addition, the growth factor VEGF, which could slow down motor neuron degeneration in rats, stimulated GluR2 expression in motor neurons and protected against excessive AMPA receptor stimulation, providing a link between two important disease mechanisms in ALS. Clinical trials with AMPA receptor antagonists and VEGF will hopefully lead to a better treatment of patients with ALS.
肌萎缩侧索硬化症(ALS)中运动神经元的进行性退化是一个复杂的多因素过程。兴奋性毒性(谷氨酸受体的过度刺激)和血管内皮生长因子(VEGF)的缺乏都与该疾病的发病机制有关。在本研究中,对这两种疾病机制进行了进一步表征,并评估了它们的治疗潜力。发现运动神经元对AMPA受体刺激(谷氨酸受体的一种亚型)特别敏感,毒性是由钙离子通过AMPA受体流入引发的。只有缺乏特定亚基(GluR2)的AMPA受体才对钙离子具有通透性,与其他神经元相比,运动神经元的GluR2水平较低。降低GluR2水平会加重培养物中运动神经元的死亡,并加速体内运动神经元的退化过程。进一步研究了GluR2表达的调节。发现星形胶质细胞会影响神经元GluR2的表达,从而影响它们对兴奋性毒性的易感性。此外,生长因子VEGF可以减缓大鼠运动神经元的退化,刺激运动神经元中GluR2的表达,并防止过度的AMPA受体刺激,这为ALS中两个重要的疾病机制之间建立了联系。使用AMPA受体拮抗剂和VEGF进行的临床试验有望为ALS患者带来更好的治疗效果。